Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05022459 · ClinicalTrials.gov registry record
Prevention of Bleeding in Patients With Moderate and Severe Hemophilia A Playing Sports: A Comparison Between Factor VIII and Emicizumab Prophylaxis
A clinical trial of Hemophilia A, sponsored by Wayne State University.
- Recruiting
- Registry status
- 72
- Enrollment target
- 9
- Study locations
NCT05022459: Recruiting study of Hemophilia A, sponsored by Wayne State University.
NCT05022459 is a study of Hemophilia A that is actively recruiting participants, run by Wayne State University. The registered enrollment target is 72 participants, below the 90-participant average among 42 other Hemophilia A trials with a reported enrollment target (20% lower). The trial reports 9 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05022459, a study of Hemophilia A, is actively recruiting participants, sponsored by Wayne State University.
- RECRUITING
- Registry status
- 72 participants
- Enrollment target
- 9
- Study locations
Study Summary
Hemophilia A (HA) is a genetic bleeding disorder resulting from a deficiency or absence of factor VIII (FVIII), which is necessary in the clotting process. This disorder occurs mostly in males and in severe cases causes frequent bleeding episodes in joints and muscles which can lead to progressive damage that affects mobility and quality of life. Prophylactic FVIII administered intravenously every other day has been the standard of care treatment for HA for the past few decades. Sports and physical activity are generally encouraged in patients with hemophilia on appropriate prophylactic treatment to increase strength, prevent or decrease obesity, accrue and maintain bone density and encourage normal socialization. To ensure safety with participation in sports in persons with hemophilia A (PWHA), timing of FVIII administration is often adjusted to maximize FVIII at the time of sports. The exact factor level that is needed to safely participate in sports and minimize bleeding risk is not yet known. Based on clinical practice, infusion of FVIII to near the lower limit of normal right before participation in sports generally works to prevent bleeding. The study is looking at how well the newly approved medication Emicizumab works compared to Factor VIII to prevent bleeding in patients with Hemophilia A who play sports. The study will enroll children and adolescents who are already on Emicizumab or Factor VIII who are currently playing sports.
Primary Outcome
Number of bleeds without trauma, during participation in sports activities
Conditions Studied
Interventions
- DRUG Emicizumab
- DRUG FVIII
Study Locations (9)
California
- Stanford University - Palo Alto
- Rady Children's Hospital - San Diego
Arkansas
- Arkansas Children's Hospital - Little Rock
Florida
- Johns Hopkins All Children's Hospital - St. Petersburg
Indiana
- Indiana Hemophilia & Thrombosis Center - Indianapolis
Massachusetts
- Boston Children's Hospital - Boston
Michigan
- Children's Hospital of Michigan - Detroit
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Oklahoma
- Oklahoma Center for Bleeding and Clotting Disorders - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2023-08-16 |
| Est. Completion | 2029-03 |
What NCT05022459 shows while recruiting
NCT05022459 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 90-participant average among 42 other Hemophilia A trials with a reported enrollment target (20% lower).
The record links to 1 condition, with Hemophilia A appearing as the primary indexed condition, and to 2 interventions - of which Emicizumab is the first listed.
NCT05022459 lists 9 locations in 8 states (California, Arkansas, Florida).
Frequently Asked Questions
What is clinical trial NCT05022459 about?
NCT05022459 is a clinical study titled "Prevention of Bleeding in Patients With Moderate and Severe Hemophilia A Playing Sports: A Comparison Between Factor VIII and Emicizumab Prophylaxis". Hemophilia A (HA) is a genetic bleeding disorder resulting from a deficiency or absence of factor VIII (FVIII), which is necessary in the clotting process. This disorder occurs mostly in males and in severe cases causes frequent bleeding episodes in joints and muscles which can lead to progressive d...
What is the current status of trial NCT05022459?
This trial is currently recruiting. The enrollment target is 72 participants. The study started on 2023-08-16. Estimated completion is 2029-03.
What conditions does trial NCT05022459 study?
This clinical trial studies the following conditions: Hemophilia A.
What interventions are being tested in trial NCT05022459?
The interventions under investigation include: Emicizumab (DRUG), FVIII (DRUG).
Who is sponsoring clinical trial NCT05022459?
This trial is sponsored by Wayne State University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05022459 being conducted?
This trial has 9 study locations across Arkansas, California, Florida, Indiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemophilia A
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05022459's enrollment target sits among peer trials
72 21st of 42 higher than 22 of 42 other Hemophilia A trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hemophilia A trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
RECRUITING · Phase 3
-
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
RECRUITING · Phase 3
-
A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A
RECRUITING · Phase 1
-
Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery
RECRUITING · Phase 4
-
Hemophilia A Research Program
RECRUITING
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI